Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.
Roche Canada is making a $500 million investment to expand its Canadian pharmaceutical headquarters in Ontario, which the company said will bring up to 500 new full-time jobs to the region over the next five years.
Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.
INCOG BioPharma Services, is a biopharmaceutical manufacturing services startup that will be establishing a manufacturing plant soon. You can get more details here.
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
The U.S. Food and Drug Administration has several PDUFA dates for the rest of October, although two of them were already approved. Here’s a look.
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
Regeneron announced that the U.S. Food and Drug Administration approved Inmazeb, a three-antibody cocktail to treat Ebola infections in adults and children.
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.